Dosing of Transdermal Estrogen and Cyclic Progesterone After Progesterone Therapy Failure
Introduction to Transdermal Estrogen and Progesterone Dosing
- The recommended dosing for patients who have failed progesterone therapy alone is transdermal estradiol patches delivering 50-100 μg daily combined with oral medroxyprogesterone acetate (Provera) 10 mg daily for 12-14 days per month in a sequential regimen, as suggested by guidelines from medical societies such as those associated with Blood Reviews 1, 2, 3
Transdermal Estrogen Dosing
- Transdermal estradiol patches should be started at a dose of 50 μg daily, which can be increased to 100 μg daily if needed for symptom control, according to the American College of Obstetricians and Gynecologists 1, 3
- Patches should be applied to clean, dry, intact skin on the lower abdomen, upper buttocks, back, or upper arms 3
- Transdermal delivery is preferred over oral administration because it avoids first-pass hepatic metabolism, provides more stable hormone levels, has a better profile for bone mass accrual, and has a lower risk of venous thromboembolism, as recommended by the Endocrine Society 1, 3
Cyclic Progesterone Dosing
- Medroxyprogesterone acetate (MPA) should be administered at a dose of 10 mg daily for 12-14 days every 28 days, as suggested by the American College of Obstetricians and Gynecologists 1, 2
- This dosing is sufficient for endometrial protection when combined with the recommended estrogen dose, according to guidelines from the North American Menopause Society 2
Alternative Progesterone Options
- Micronized progesterone 200 mg daily for 12-14 days per month is a recommended alternative due to its better cardiovascular and thrombotic risk profile, as suggested by the American Heart Association 1, 2
- Dydrogesterone 10 mg daily for 12-14 days per month and vaginal progesterone 200 mg daily for 12-14 days per month are also alternative options, according to the European Menopause and Andropause Society 2
Monitoring and Follow-up
- Treatment effect should be evaluated after 3-6 months, and annual clinical reviews should be conducted to assess compliance and side effects, as recommended by the American College of Obstetricians and Gynecologists 2, 3
- No routine laboratory monitoring is required unless prompted by specific symptoms, according to guidelines from the National Institute for Health and Care Excellence 3
Important Considerations
- If withdrawal bleeding is not desired, consider continuous combined regimens using lower progesterone doses, such as 2.5 mg MPA daily or 5 mg dydrogesterone daily, as suggested by the Endocrine Society 1, 2
- For women requiring contraception, consider 17β-estradiol-based combined oral contraceptives, according to the American College of Obstetricians and Gynecologists 1, 2
Combined Estrogen and Progesterone Options
- Combined transdermal patches containing both estrogen and progestin are available in some countries and may improve compliance, as noted by the European Menopause and Andropause Society 1